KDC-MN-241 – Kodiac biolabs

Plain-language summaryIntrigue 76 / 100

Ulotaront (SEP-363856) was an exciting investigational antipsychotic from Sumitomo (Sunovion) that worked through a completely different mechanism than every other drug in its class: activation of the trace amine-associated receptor 1 (TAAR1) plus serotonin 5-HT1A activation, with no measurable activity at dopamine D2 or serotonin 5-HT2A receptors at all. The Phase 2 data published in the New England Journal of Medicine in 2020 generated significant enthusiasm, suggesting it might be the first non-D2 antipsychotic ever to reach approval. The Phase 3 DIAMOND trials read out in 2023 and failed to demonstrate efficacy versus placebo, which was a substantial disappointment for the field. The TAAR1 mechanism remains under active investigation by other companies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

67/100

First-in-class TAAR1/5-HT1A dual agonist with a genuinely novel antipsychotic mechanism, tempered by a failed Phase 3

Look, ulotaront is genuinely interesting and we’d be lying if we said otherwise. The compound reached Phase 3 for schizophrenia without touching dopamine D2 or serotonin 5-HT2A, the two receptors every single approved antipsychotic has relied on since chlorpromazine in the 1950s. That’s not a minor formulation tweak. That’s the entire theoretical basis of antipsychotic pharmacology being rewritten, and the fact that it actually got this far clinically is worth taking seriously.

The discovery story matters here. Sunovion and PsychoGenics identified this through phenotypic screening on the SmartCube automated behavioral platform, not through rational TAAR1 design. The molecular target was deconvoluted after the fact, which means the behavioral profile came first and the mechanistic explanation came second. What they found was full agonism at human TAAR1 (EC50 roughly 38 to 140 nM, Emax around 101 percent) and partial agonism at 5-HT1A (EC50 approximately 2.3 micromolar, Emax around 75 percent). No D2 antagonism. No 5-HT2A antagonism. The EPS, metabolic syndrome, and hyperprolactinemia liabilities that define every approved antipsychotic should, in theory, not apply.

The Phase 2 data (Koblan et al., 2020, NEJM) was genuinely encouraging. Statistically significant improvement on PANSS total score versus placebo across a 4-week acute trial, with a tolerability profile cleaner than anything currently approved. FDA issued Breakthrough Therapy Designation. Then Phase 3 hit. The DIAMOND program came back negative, and thats a real blow to the translational narrative for acute schizophrenia. It doesn’t mean the mechanism is wrong, but it does mean the Phase 2 signal didn’t hold under tighter conditions. Why it failed is itself a research problem, and we think that question is live and interesting.

Here’s what keeps ulotaront worth studying despite the Phase 3 result. TAAR1 biology remains poorly characterized, and ulotaront is currently the best available probe for human TAAR1 function in a clinical context. The receptor sits in dopaminergic and serotonergic circuits, connects to metabolic regulation, sleep architecture, and possibly abuse liability. Ralmitaront (RO6889450) is the only real comparator and it’s less clinically advanced. For any bench program interrogating trace amine receptor biology, TAAR1-dopamine circuit interactions, or next-generation CNS pharmacology that isn’t D2-dependent, ulotaront is the reference compound right now.

We’ve scored the Phase 3 failure honestly. Translational signal takes the hit it deserves, and the evidence score reflects that Phase 2 positive data didn’t replicate forward cleanly. What doesnt change is the novelty of the mechanism, the clean differentiation from every approved antipsychotic, and the bench utility for TAAR1 research programs. This is worth knowing well. Just don’t carry forward the Phase 2 story as if the Phase 3 data doesn’t exist.

Novelty: 75
Mechanism promise: 80
In-category differentiation: 75
Evidence quality: 52
Translational signal: 42
Research bench value: 65

Rationale Ulotaront earns high novelty and mechanism scores as the first TAAR1 agonist to reach Phase 3 and the only antipsychotic candidate operating entirely without D2/5-HT2A antagonism; the DIAMOND Phase 3 negative readout materially depresses translational signal and evidence scores, landing the overall in the 65-70 range despite the genuine mechanistic distinction.

Trace amine-associated receptor 1 (TAAR1) full agonist with serotonin 5-HT1A receptor partial agonism

A first-in-class TAAR1/5-HT1A dual agonist discovered through phenotypic screening, developed for schizophrenia under FDA Breakthrough Therapy Designation, and distinguished from all approved antipsychotics by the absence of dopamine D2 and serotonin 5-HT2A receptor antagonism.

Abstract

Ulotaront (SEP-363856) is a thienopyran-based small molecule and the first trace amine-associated receptor 1 (TAAR1) agonist to reach Phase 3 clinical development for the treatment of schizophrenia. Discovered through a target-agnostic phenotypic screening collaboration between PsychoGenics and Sunovion Pharmaceuticals (now Sumitomo Pharma), ulotaront was identified using the SmartCube automated behavioral platform rather than rational design against TAAR1, and its molecular target was subsequently deconvoluted to reveal full agonism at human TAAR1 (EC50 approximately 38 to 140 nM, Emax approximately 101 to 109 percent) and partial agonism at the serotonin 5-HT1A receptor (EC50 approximately 2.3 micromolar, Emax approximately 75 percent). The compound is not an antagonist at either the dopamine D2 or the serotonin 5-HT2A receptor, the two canonical targets of all currently approved first-generation and second-generation antipsychotics. This mechanistic distinction positions ulotaront as a fundamentally novel pharmacological approach to psychotic disorders, with a preclinical and early clinical profile that suggests potential advantages in the avoidance of extrapyramidal symptoms, metabolic syndrome, hyperprolactinemia, and sedation that limit the tolerability of existing antipsychotic therapies.

In preclinical models, ulotaront dose-dependently reduced phencyclidine-induced hyperlocomotion, restored prepulse inhibition deficits, increased social interaction in chronic phencyclidine paradigms, and ameliorated cognitive impairments, all without producing catalepsy at doses up to 100 mg/kg. The compound prevented olanzapine-induced weight gain in rodents and demonstrated no effect on prolactin release. Pharmacokinetics are characterized by rapid oral absorption, greater than 70 percent bioavailability in preclinical species, high blood-brain barrier penetration (brain concentrations approximately threefold higher than plasma), a median effective half-life of approximately 7 hours in humans supporting once-daily dosing, and predominant hepatic metabolism through CYP2D6. The compound received FDA Breakthrough Therapy Designation in May 2019 on the basis of a positive Phase 2 randomized controlled trial (Koblan et al., 2020) in 245 acutely psychotic adults with schizophrenia, in which ulotaront at 50 to 75 mg/day produced a statistically significant reduction in Positive and Negative Syndrome Scale (PANSS) total score of 17.2 points versus 9.7 points on placebo at four weeks (effect size 0.45, p less than 0.001), with concurrent improvement on negative symptom, depressive symptom, and global severity measures. A 26-week open-label extension demonstrated sustained improvement (PANSS total reduction of 41.8 points from double-blind baseline) with a favorable metabolic and movement disorder safety profile.

The Phase 3 DIAMOND program, however, produced negative results. DIAMOND 1 (ulotaront 50 and 75 mg/day versus placebo in 435 patients) and DIAMOND 2 (ulotaront 75 and 100 mg/day versus placebo in 464 patients) both failed to meet their primary endpoints at six weeks, with large placebo responses potentially masking the therapeutic signal. Additional Phase 3 studies (DIAMOND 3, long-term extension, and a switch study versus quetiapine) were planned or ongoing at the time of the negative readouts. Despite the Phase 3 setback in schizophrenia, ulotaront continues in Phase 2/3 development for generalized anxiety disorder and as adjunctive therapy in major depressive disorder, reflecting the broader neuropsychiatric potential of the TAAR1 mechanism. This monograph reviews the chemistry, discovery, molecular pharmacology, comprehensive pharmacokinetics, preclinical and clinical evidence across all studied indications, sourcing and handling considerations, stack interactions, adverse events, and a comparative assessment of five alternative approaches to non-dopaminergic antipsychotic pharmacology against ulotaront on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1501Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-241

Ulotaront

Abstract

Read the full monograph